Related Experiment Video
Updated: Feb 1, 2026

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors
Marco Barazas1, Alessia Gasparini2, Yike Huang1
1Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Abstract:
The defect in homologous recombination (HR) found in BRCA1-associated cancers can be therapeutically exploited by treatment with DNA-damaging agents and PARP inhibitors. We and others previously reported that BRCA1-deficient tumors are initially hypersensitive to the inhibition of topoisomerase I/II and PARP, but acquire drug resistance through restoration of HR activity by the loss of end-resection antagonists of the 53BP1/RIF1/REV7/Shieldin/CST pathway. Here, we identify radiotherapy as an acquired vulnerability of 53BP1;BRCA1-deficient cells in vitro and in vivo. In contrast to the radioresistance caused by HR restoration through BRCA1 reconstitution, HR restoration by 53BP1 pathway inactivation further increases radiosensitivity. This highlights the relevance of this pathway for the repair of radiotherapy-induced damage. Moreover, our data show that BRCA1-mutated tumors that acquire drug resistance due to BRCA1-independent HR restoration can be targeted by radiotherapy. SIGNIFICANCE: These findings uncover radiosensitivity as a novel, therapeutically viable vulnerability of BRCA1-deficient mouse mammary cells that have acquired drug resistance due to the loss of the 53BP1 pathway.
Insights
BRCA1-deficient cancers initially respond to DNA-damaging agents but develop resistance. Loss of the 53BP1 pathway restores homologous recombination (HR) but creates a new vulnerability to radiotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- BRCA1-associated cancers exhibit homologous recombination (HR) defects, making them sensitive to DNA-damaging agents and PARP inhibitors.
- Acquired resistance to these therapies in BRCA1-deficient tumors is often linked to the restoration of HR activity via loss of 53BP1 pathway antagonists.
Purpose of the Study:
- To investigate radiotherapy as a potential therapeutic strategy for drug-resistant BRCA1-deficient cancers.
- To explore the role of the 53BP1 pathway in acquired radioresistance.
Main Methods:
- Utilized in vitro and in vivo models of 53BP1;BRCA1-deficient cells.
- Assessed cellular responses to radiotherapy.
- Analyzed the impact of HR restoration via BRCA1 reconstitution versus 53BP1 pathway inactivation on radiosensitivity.
Main Results:
- Inactivation of the 53BP1 pathway in BRCA1-deficient cells leads to acquired radiosensitivity, contrasting with radioresistance from BRCA1 reconstitution.
- The 53BP1 pathway is crucial for repairing radiotherapy-induced DNA damage.
- BRCA1-mutated tumors with acquired drug resistance through BRCA1-independent HR restoration are susceptible to radiotherapy.
Conclusions:
- Radiosensitivity represents a novel therapeutic vulnerability in BRCA1-deficient cancers that have acquired drug resistance by losing the 53BP1 pathway.
- Targeting this pathway could offer new treatment options for resistant BRCA1-mutated tumors.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:22Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
Published on: February 28, 2021
Related Concept Videos
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Rolling Resistance
For instance, imagine a hard cylinder rolling on a comparatively soft surface. The cylinder's weight compresses the surface beneath it. As the cylinder moves, the material in front of it slows down due to...
Vascular Resistance
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...